Vanguard Capital Management
TGTX icon

Vanguard Capital Management’s TG Therapeutics TGTX Stock Holding History

Vanguard Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$338M Sell
6,149,403
-453,855
-7% -$18.6M 0.01% 857
2026
Q1 		$219M Buy
+6,603,258
New +$197M 0.01% 1016

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management's TGTX Position: Q2 2026 in Review

Vanguard Capital Management reduced its TG Therapeutics (TGTX) stake by 6.9% in Q2 2026, selling an estimated $18.6M and leaving 6,149,403 shares worth $338M. The position accounts for 0.01% of the portfolio, ranked #857.

Vanguard Capital Management first reported a position in TGTX in Q1 2026 and has held it in 2 quarters since. 423 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Vanguard Capital Management held 6,149,403 shares of TG Therapeutics worth $338M as of Q2 2026.
  • Vanguard Capital Management sold 453,855 TG Therapeutics shares in Q2 2026, an estimated $18.6M.
  • TG Therapeutics made up 0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #857 holding.
  • Vanguard Capital Management first reported a position in TG Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 423 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.